HBCN Stock Overview
HealthBeacon plc, a digital therapeutics company, develops products for managing injectable medications for patients in the home in Europe, the United States, and Ireland.
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.74|
|52 Week High||€6.24|
|52 Week Low||€2.60|
|1 Month Change||5.39%|
|3 Month Change||-37.73%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-53.24%|
Recent News & Updates
HealthBeacon (ISE:HBCN) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|HBCN||IE Medical Equipment||IE Market|
Return vs Industry: Insufficient data to determine how HBCN performed against the Irish Medical Equipment industry.
Return vs Market: Insufficient data to determine how HBCN performed against the Irish Market.
|HBCN Average Weekly Movement||n/a|
|Medical Equipment Industry Average Movement||6.8%|
|Market Average Movement||5.6%|
|10% most volatile stocks in IE Market||9.3%|
|10% least volatile stocks in IE Market||3.9%|
Stable Share Price: Insufficient data to determine HBCN's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine HBCN's volatility change over the past year.
About the Company
HealthBeacon plc, a digital therapeutics company, develops products for managing injectable medications for patients in the home in Europe, the United States, and Ireland. Its injection care management system tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence driven data analytics. The company also sells and leases medical adherence technology devices and injection care management systems.
HealthBeacon Fundamentals Summary
|HBCN fundamental statistics|
Is HBCN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HBCN income statement (TTM)|
|Cost of Revenue||€1.91m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.48|
|Net Profit Margin||-370.78%|
How did HBCN perform over the long term?See historical performance and comparison
Is HBCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HBCN?
Other financial metrics that can be useful for relative valuation.
|What is HBCN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HBCN's PS Ratio compare to its peers?
|HBCN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TRIB Trinity Biotech
KEQU Kewaunee Scientific
BOUL Boule Diagnostics
Price-To-Sales vs Peers: HBCN is expensive based on its Price-To-Sales Ratio (21x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does HBCN's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Sales vs Industry: HBCN is expensive based on its Price-To-Sales Ratio (21x) compared to the European Medical Equipment industry average (5.8x)
Price to Sales Ratio vs Fair Ratio
What is HBCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||21x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate HBCN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of HBCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HBCN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HBCN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is HealthBeacon forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HBCN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: HBCN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HBCN is expected to become profitable in the next 3 years.
Revenue vs Market: HBCN's revenue (89.5% per year) is forecast to grow faster than the Irish market (8.3% per year).
High Growth Revenue: HBCN's revenue (89.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HBCN's Return on Equity is forecast to be low in 3 years time (12%).
Discover growth companies
How has HealthBeacon performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: HBCN is currently unprofitable.
Growing Profit Margin: HBCN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HBCN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HBCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBCN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Return on Equity
High ROE: HBCN has a negative Return on Equity (-28.05%), as it is currently unprofitable.
Discover strong past performing companies
How is HealthBeacon's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HBCN's short term assets (€29.1M) exceed its short term liabilities (€3.6M).
Long Term Liabilities: HBCN's short term assets (€29.1M) exceed its long term liabilities (€112.0K).
Debt to Equity History and Analysis
Debt Level: HBCN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if HBCN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HBCN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HBCN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.9% each year
Discover healthy companies
What is HealthBeacon current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HBCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBCN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBCN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HBCN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Joyce (51 yo)
Mr. James Joyce, also known as Jim, serves as Chief Executive Officer for HealthBeacon plc and has been its Executive Director since July 25, 2013. Mr. Joyce co-founded HealthBeacon plc in 2013. He served...
Experienced Management: HBCN's management team is considered experienced (2.8 years average tenure).
Experienced Board: HBCN's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: HBCN only recently listed within the past 12 months.
HealthBeacon plc's employee growth, exchange listings and data sources
- Name: HealthBeacon plc
- Ticker: HBCN
- Exchange: ISE
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €46.552m
- Shares outstanding: 16.99m
- Website: https://www.healthbeacon.com
Number of Employees
- HealthBeacon plc
- Unit 20, Naas Road Business Park
- Muirfield Drive
- Co. Dublin
- D12 WD85
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.